AZD9567

AZD9567 is an investigational drug developed by AstraZeneca for the treatment of inflammatory diseases. It is a selective glucocorticoid receptor modulator (SGRM) designed to provide the anti-inflammatory benefits of traditional glucocorticoids while minimizing their side effects.

Mechanism of Action

AZD9567 works by selectively modulating the glucocorticoid receptor, which plays a crucial role in regulating the body's response to inflammation. Unlike traditional glucocorticoids, which can cause significant side effects such as osteoporosis, hyperglycemia, and muscle wasting, AZD9567 aims to reduce these adverse effects by targeting specific pathways involved in the inflammatory response.

Clinical Development

AZD9567 is currently undergoing clinical trials to evaluate its efficacy and safety in treating various inflammatory conditions, including rheumatoid arthritis and inflammatory bowel disease. Early-phase studies have shown promising results, indicating that AZD9567 may offer a safer alternative to conventional glucocorticoid therapy.

Potential Benefits

The development of AZD9567 represents a significant advancement in the treatment of inflammatory diseases. By selectively targeting the glucocorticoid receptor, AZD9567 has the potential to provide effective anti-inflammatory action with a reduced risk of side effects. This could improve the quality of life for patients who require long-term glucocorticoid therapy.

Related Pages

• AstraZeneca
• Glucocorticoid receptor
• Rheumatoid arthritis
• Inflammatory bowel disease
• Osteoporosis
• Hyperglycemia
• Muscle wasting

See Also

• Selective glucocorticoid receptor modulator
• Anti-inflammatory drugs
• Clinical trials